By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics today said it has entered into purchase agreements with investors to raise more than $7.8 million.

The agreement is for a private placement of 5.3 million new shares of its common stock priced at $1.50 per share. The financing comes from mostly new investors, the Los Angeles-based molecular diagnostics firm said, with existing investors, board members, and senior management also participating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.